SCHEMBL131063

SCHEMBL131063

N#CC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 5/20 0.38
GRIN3B O60391 5/20 0.38
GRIN1 Q05586 5/20 0.38
GRIN2A Q12879 5/20 0.38
GRIN2B Q13224 5/20 0.38
GRIN2C Q14957 5/20 0.38
GRIN3A Q8TCU5 5/20 0.38
LMNA P02545 3/20 0.38
SLC22A2 O15244 2/20 0.38
SLC47A1 Q96FL8 2/20 0.38
SLC22A1 O15245 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
STAT6 P42226 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16804791 0.87
SCHEMBL14641099 0.82 PGR (0.32)
SCHEMBL19135850 0.82
SCHEMBL20749582 0.82
SCHEMBL16713932 0.80
SCHEMBL1035502 0.80 HSD11B1 (0.32) HSD11B1
SCHEMBL12378023 0.78 HSD11B1 (0.34) HSD11B1
SCHEMBL328811 0.78 HSD11B1 (0.32) HSD11B1
SCHEMBL12324777 0.78 HSD11B1 (0.36) HSD11B1
SCHEMBL8580089 0.77 EPHX2 (0.43) TSHRALDH1A1NPSR1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2025-05-20 US claimed
EP-4407011-A1 GLASS CRYSTAL-BASED ACTIVELY-CONTROLLABLE BAROCALORIC MATERIAL SOLID STATE PHASE TRANSFORMATION HEAT STORAGE AND HEAT RELEASE METHOD, APPARATUS AND USES Institute of Metal Research, Chinese Academy of Sciences (CN) 2024-07-31 EP claimed
CN-114350325-B Glass crystal-based actively controllable solid-state phase change heat storage and release method, device and application of press card material 中国科学院金属研究所 2023-10-03 CN claimed
CN-116793129-A Fine controllable heat release device based on plastic crystal glass crystal phase, heat release method and application thereof 中国科学院金属研究所 2023-09-22 CN claimed
WO-2023133909-A1 GLASS CRYSTAL-BASED ACTIVELY-CONTROLLABLE BAROCALORIC MATERIAL SOLID STATE PHASE TRANSFORMATION HEAT STORAGE AND HEAT RELEASE METHOD, APPARATUS AND USES 中国科学院金属研究所 2023-07-20 WO claimed
CN-115468688-A Method for realizing pressure sensing based on response of glass crystal to pressure and application thereof 中国科学院金属研究所 2022-12-13 CN claimed
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2022-06-23 US claimed
CN-114350325-A Glass crystal-based active and controllable solid-state phase change heat storage and heat release method and device for card pressing material and application 中国科学院金属研究所 2022-04-15 CN claimed
WO-2020210922-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11Β-HSD1) PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2020-10-22 WO claimed
EP-3636641-A1 ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2020-04-15 EP claimed
EP-2272825-B1 Protected amino hydroxy adamantane carboxylic acid and process for its preparation ASTRAZENECA AB (SE) 2015-11-04 EP claimed
EP-1948736-B1 PROCESS FOR PREPARING FLAKE-FORM PARTICLES BASF SE (DE) 2011-03-16 EP claimed
EP-2272825-A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation Bristol-Myers Squibb Company (US) 2011-01-12 EP claimed
US-20100062244-A1 Process for Preparing Flake-Form Particles CIBA CORPORATION (US) 2010-03-11 US claimed
EP-1948736-A1 PROCESS FOR PREPARING FLAKE-FORM PARTICLES Ciba Holding Inc. (CH) 2008-07-30 EP claimed
CN-101031595-A One-component cationic palladium pre-initiator for the latent polymerization of cycloolefins PROMERUS LLC (US) 2007-09-05 CN claimed
WO-2007057328-A1 PROCESS FOR PREPARING FLAKE-FORM PARTICLES CIBA HOLDING INC. (CH) 2007-05-24 WO claimed
EP-1559710-A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use Bristol-Myers Squibb Company (US) 2005-08-03 EP claimed
US-4894180-A Liquid crystal optical element FUJI PHOTO FILM CO., LTD. (JP) 1990-01-16 US claimed
EP-0178668-A2 Process for preparing rimantadine E.I. DU PONT DE NEMOURS AND COMPANY (US) 1986-04-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) HSD11B1, HSD11B2, CYP11B1 GRIN2D 483/4885GRIN3B 726/4885GRIN1 438/4885
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) HSD11B1, HSD11B2, HSD17B1 GRIN2D 495/4885GRIN3B 803/4885GRIN1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.